Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/2/2010

SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 10:00 a.m. EST (7:00 a.m. PST).  The conference is being held at the Waldorf-Astoria Hotel in New York.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Additionally, Dr. Worland will participate as a panelist on the BIO CEO & Investor Conference HCV Panel on Tuesday, February 9, 2010 at 12:00 p.m. EST (9:00 a.m. PST).

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through February 23, 2010.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C.  The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE Anadys Pharmaceuticals, Inc.

RELATED LINKS
http://www.anadyspharma.com

'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
2. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
3. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
7. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... February 24, 2017 Following receiving ... Israel , s AMAR is a major ... 250 M w ound care market in ... BST for inclusion in the National Health Basket ...   E-QURE Corp. (OTCQB: EQUR), a leader ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... 24, 2017 Physician General Dr. Rachel ... Programs Jennifer Smith commended South Central EMS ... and using naloxone, a life-saving overdose reversal drug. The ... recovery specialist and overdose survivor who was saved due ... "A significant part of fighting the opioid epidemic ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... options at his office, Antoine Dental Center. Currently, patients can get single dental ... may apply, but patients can learn more about these offers by contacting Antoine ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. ... has officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio ...
(Date:2/24/2017)... York, NY (PRWEB) , ... February 24, 2017 , ... ... “Security needs to be a top priority because it’s not if you will be ... online safety, especially when it comes to digital health care. , Improvements in auditing ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
Breaking Medicine News(10 mins):